White Paper

Solving Imminent Regulatory Challenges With Single Use Technologies For mRNA Vaccine Production

Source: Chargepoint Technology

By Ben Wylie

mRNA iStock-1287178753

The market for mRNA (messenger Ribonucleic Acid) vaccine technology is expanding rapidly. mRNA vaccines stimulate the immune response in a patient’s body. Instead of the vaccine containing a weakened/inactivated form of the virus, the vaccine contains genetic material coding for a disease-specific protein to the virus. Though manufacturing, mRNA technology comes with a list of challenges, the biggest obstacle being achieving compliance with GMP Annex 1 regulations. Here, we dive into the compliance issue and explain how companies who want to use mRNA vaccine technology can address challenges through the use of single-use technologies (SUTs).

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online